GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » E10

Kiora Pharmaceuticals (Kiora Pharmaceuticals) E10 : $-568.08 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kiora Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.294. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-568.08 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-01), Kiora Pharmaceuticals's current stock price is $0.545. Kiora Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-568.08. Kiora Pharmaceuticals's Shiller PE Ratio of today is .


Kiora Pharmaceuticals E10 Historical Data

The historical data trend for Kiora Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals E10 Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -604.88 -568.08

Kiora Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -604.88 -598.26 -590.69 -582.82 -568.08

Competitive Comparison of Kiora Pharmaceuticals's E10

For the Biotechnology subindustry, Kiora Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Shiller PE Ratio falls into.



Kiora Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kiora Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.294/129.4194*129.4194
=-0.294

Current CPI (Dec. 2023) = 129.4194.

Kiora Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -108.193 99.695 -140.452
201406 -79.331 100.560 -102.098
201409 26.763 100.428 34.489
201412 -36.004 99.070 -47.034
201503 -1,937.990 99.621 -2,517.674
201506 -143.999 100.684 -185.097
201509 -113.999 100.392 -146.961
201512 -143.999 99.792 -186.750
201603 -185.999 100.470 -239.592
201606 -275.999 101.688 -351.267
201609 -215.999 101.861 -274.437
201612 -227.999 101.863 -289.679
201703 -167.999 102.862 -211.373
201706 -167.999 103.349 -210.378
201709 -143.999 104.136 -178.962
201712 -90.000 104.011 -111.986
201803 -84.000 105.290 -103.251
201806 -42.000 106.317 -51.127
201809 -43.200 106.507 -52.494
201812 -30.800 105.998 -37.606
201903 7.600 107.251 9.171
201906 -25.200 108.070 -30.178
201909 -46.000 108.329 -54.955
201912 -30.400 108.420 -36.288
202003 -17.200 108.902 -20.441
202006 -15.200 108.767 -18.086
202009 -17.600 109.815 -20.742
202012 -9.600 109.897 -11.305
202103 -10.800 111.754 -12.507
202106 -13.600 114.631 -15.354
202109 -11.340 115.734 -12.681
202112 -21.430 117.630 -23.578
202203 -11.270 121.301 -12.024
202206 -7.200 125.017 -7.454
202209 -6.030 125.227 -6.232
202212 -1.391 125.222 -1.438
202303 -1.000 127.348 -1.016
202306 -0.790 128.729 -0.794
202309 -0.890 129.860 -0.887
202312 -0.294 129.419 -0.294

Add all the adjusted EPS together and divide 10 will get our e10.


Kiora Pharmaceuticals  (NAS:KPRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kiora Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.
Executives
Carmine N. Stengone director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca officer: EVP of Finance C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler officer: Interim CFO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
David Hollander director C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem director, officer: President and CEO C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels officer: Chief Development Officer C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro director C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron director 75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr officer: Acting CEO C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110